Artelo Biosciences filed a provisional patent application covering ART27.13 as a standalone obesity treatment and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic and Wegovy. In the company’s four-week DIO-2 study, ART27.13 produced approximately 20% weight loss as monotherapy and approximately 40% when combined with semaglutide in obese mice, with about 80% of weight lost in ART27.13-treated groups coming from fat. The combination also suppressed appetite more than semaglutide alone, improved oral glucose tolerance and increased bone mineral density, an effect not seen in other treatment groups. Artelo said the findings expand its obesity research and intellectual property position, while noting that the results are preliminary, the program is at an early stage and animal findings may not translate to humans. J.P. Morgan has projected that the global GLP-1 market could reach $200 billion by 2030.